23andMe, a leading DNA-testing company, will lay off 40% of its staff—approximately 200 jobs—as it seeks to stabilize amid significant financial challenges. The company also announced it will discontinue the development of new therapies. This decision follows a year marked by a severe drop in share prices, over 70%, and a data breach exposing personal information of millions of users. Co-founder and CEO Anne Wojcicki is facing pressure to implement effective turnaround strategies.